Wearable Biosensors for Malaria Detection
What You Need to Know Before You Apply
What is the purpose of this trial?
In order to control infections, the investigators must first detect them. Biosensor devices may allow early detection and intervention for infectious diseases, helping the investigators to recognize infections early, and allow for early treatment. This will lower transmission of infections and lower costs for treating someone who becomes ill. This is a study testing whether a wearable device such as a wristband and/or earphones can measure early biologic signals to detect identify infection in prior to seeing symptoms related of a disease. As a first test of this technology, the investigators will expose participants to injectable malaria or placebo. This is called a "Controlled Human Malaria Infection" (CHMI). Everyone who takes part in the CHMI may get malaria infection. The investigators will detect malaria using standard blood tests. The investigators will also look for early symptoms of malaria infection like changes in temperature, heart rate, breathing, sleep patterns, and changes in skin and muscle activity or voice. These signals may allow the investigators to detect early malaria infection. This is a study testing whether a wearable device such as a wristband and/or earphones can measure early biologic signals to detect malaria infection before symptoms occur, as confirmed by standard blood testing.
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Controlled Human Malaria Infection (CHMI)
Participants are exposed to injectable malaria or placebo to test the biosensor devices for early detection of malaria infection.
Follow-up
Participants are monitored for safety and effectiveness after exposure to malaria infection.
What Are the Treatments Tested in This Trial?
Interventions
- PfSPZ Challenge (NF54)
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
0.5 mL single-dose of PfSPZ Challenge (strain NF54)
Normale saline placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Maryland, Baltimore
Lead Sponsor
Bill and Melinda Gates Foundation
Collaborator
Sanaria Inc.
Industry Sponsor
University of Texas at Austin
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.